

Hikma Europe factsheet

hikma.

January 2026

Hikma is a global pharmaceutical company listed on the London Stock Exchange providing customers across North America, MENA and Europe with a broad range of generic, specialty and branded pharmaceutical products. Hikma has an established and growing presence in Europe, having operated there since the 1990s.

Through our high-quality manufacturing plants in Portugal, Italy and Germany, we supply generic injectable medicines to North America, Europe, and Middle East and North Africa (MENA).

Local expertise, global strength



3 locations with **5** manufacturing plants



1,300+
skilled employees



1
R&D hub



7
commercial offices

R&D hub



Zagreb,
Croatia

Integrated CMO services

Our contract manufacturing integrated services for injectable products offer a range of capabilities, ensuring high-quality at every stage and supporting our partners needs from industrial process development all the way to commercial manufacturing.

Manufacturing capabilities

With an installed capacity of over 500 million units, expansion is underway in both the EU and the US.

Sintra, Portugal, the global hub for the Injectables business:

- Three segregated plants for the manufacturing of general formulation products, high containment products and Cephalosporins antibiotics
- Our capabilities cover different forms and technologies, including vials and ampoules, prefilled syringes, IV bags, emulsions/suspensions and oils
- The site services, the US, EU, UK and MENA markets

Goslar, Germany:

- One plant
- Our capabilities include cytotoxic manufacturing of both liquid and lyophilised vials
- The site services the US, EU and MENA markets

Pavia, Italy:

- One plant
- Our capabilities include liquid and lyophilised vials, and liquid ampoules
- The site services the EU and MENA markets

Commercial offices

We supply high-quality medicines to European hospitals and retail markets.

BENELUX

France

Germany and Austria

Italy

Portugal

Spain

UK and Nordics



Therapy areas



Anti-infectives



Central Nervous System



Cardiovascular



Oncology



Musculoskeletal



Respiratory



Digestive and metabolic system



Anti-neoplastics and Hormonal therapy

Company information

Chairman and CEO:
Said Darwazah

Chief Financial Officer:
Khalid Nabilsi

Hikma Pharmaceuticals PLC

1 New Burlington Place London
W1S 2HR, UK

Contacts

See www.hikma.com for contact forms